Log in
ASX:MEB

Medibio Limited (MEB.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.01
MA: A$0.01
A$0.01
52-Week Range N/A
Volume1.26 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Medibio Limited, a health technology company, researches, develops, and commercializes mental health technology to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions in Australia and the United States. It offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. Medibio Limited has a clinical trial agreement with MedBridge Healthcare LLC to support Medibio's sleep analysis of depressive burden (SADB) trial. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was incorporated in 1987 and is based in Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.40 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone952-222-0551
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$925,269.00
Book ValueA$0.01 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive MEB News and Ratings via Email

Sign-up to receive the latest news and ratings for MEB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Medibio Limited (MEB.AX) (ASX:MEB) Frequently Asked Questions

What stocks does MarketBeat like better than Medibio Limited (MEB.AX)?

Wall Street analysts have given Medibio Limited (MEB.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medibio Limited (MEB.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Medibio Limited (MEB.AX)'s key competitors?

Who are Medibio Limited (MEB.AX)'s key executives?

Medibio Limited (MEB.AX)'s management team includes the following people:
  • Mr. Claude Solitario, Managing Director, CEO & Director
  • Ms. Melanie Jaye Leydin C.A., B.Bus, CA, Joint Company Sec. & Director (Age 47, Pay $141.63k)
  • Ms. Renee Stanton-Horne, Operations & Account Mang.
  • Ms. Stephanie Ottens, Investor Relations Director
  • Mr. Josh Purdy, PR Director
  • Dr. Michael Player, Head of Research
  • Dr. Matthew Flax, Head of Algorithm Devel. Team
  • Mr. Archie Defillo M.D., Chief Medical Officer
  • Ms. Jennifer Solitario, Sr. VP of Corp. Health
  • Mr. Massimiliano Grassi, Head of Artificial Intelligence

What is Medibio Limited (MEB.AX)'s stock symbol?

Medibio Limited (MEB.AX) trades on the ASX under the ticker symbol "MEB."

How big of a company is Medibio Limited (MEB.AX)?

Medibio Limited (MEB.AX) has a market capitalization of $0.00 and generates $925,269.00 in revenue each year.

What is Medibio Limited (MEB.AX)'s official website?

The official website for Medibio Limited (MEB.AX) is www.medibio.com.au.

How can I contact Medibio Limited (MEB.AX)?

The company can be reached via phone at 952-222-0551.

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.